Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.06), $0.04 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• SpaceX bond sale draws $89 billion in investor demand
• Meta plans to build prediction markets app called Arena - NYT